Quality small and large molecule bioanalysis for drug development



Leveraging 30 Years of Experience

Learn More
CMIC delivers highly accurate, timely results in days!


Delivering highly accurate, timely results in days!

Learn More
Purpose Built Bioanalytical Facility and World Class Technology


Purpose Built Facility and World Class Technology

View More

Performing bioanalysis with uncompromising precision

Pharmaceutical Value Creator

CMIC is a bioanalytical Contract Research Organization (CRO) offering:

Preclinical and Clinical Bioanalysis

CMIC delivers highly accurate bioanalytical results for non-clinical and clinical projects, both GLP and non-GLP. As your strategic partner, we are able to streamline your drug development efforts.

Small and Large Molecules, Oligonucleotides, Peptides, Proteins, Monoclonal Antibodies

CMIC is a CRO focusing on supporting drug development from small molecules to biologics

Custom Exploratory Biomarkers

CMIC offers custom exploratory biomarker services for development, validation and sample analysis. We make sure biomarker results are accurate and reliable.

Laboratories in US and Japan

Our state-of-the-art facility, modeled after sister labs in Japan has the capacity to accommodate quick turnaround and high volume projects from around the country.

Experience, Quality and Results

CMIC is a global Contract Research OrganizationPurpose built in 2010, CMIC’s contract bioanalytical and biomarker laboratory is just 25 minutes West of Chicago O’Hare International and is one of four global contract laboratories in the CMIC Holdings group. CMIC is the first and largest Japan based CRO with nearly $600 Mil. in revenue and 6,000 employees worldwide. We aspire to be the top provider of bioanalytical and biomarker services in the world by excellence in communication and customer service, unquestionable data quality and rapid turnaround times; this how we earned the position as the number one lab in Japan for over 30 years and this is how we are growing in the US. In Spring of 2017, to support growing demand, we will open a newly expanded 26,000 sq. ft. facility with 17 LC-MS/MS instruments (bringing CMIC global count to 47 LC-MS/MS) instruments and with a full suite of advanced testing capabilities and sample storage space to support 50 freezers. We are eager to let you put our aspirations to the test and welcome the opportunity to discuss your next projects.

"Our vision is to be recognized as a leader in bioanalytical services that clients can trust to deliver high quality data, rapid turnaround, and unparalleled customer service while making every project a success."

Mike Suga
President and CEO

Kunio Momiyama, President and CEO CMIC